Convection-enhanced delivery of M13 bacteriophage to the brain

Laboratory investigation

Restricted access

Object

Recent studies indicate that M13 bacteriophage, a very large nanoparticle, binds to β-amyloid and α-synuclein proteins, leading to plaque disaggregation in models of Alzheimer and Parkinson disease. To determine the feasibility, safety, and characteristics of convection-enhanced delivery (CED) of M13 bacteriophage to the brain, the authors perfused primate brains with bacteriophage.

Methods

Four nonhuman primates underwent CED of M13 bacteriophage (900 nm) to thalamic gray matter (4 infusions) and frontal white matter (3 infusions). Bacteriophage was coinfused with Gd-DTPA (1 mM), and serial MRI studies were performed during infusion. Animals were monitored for neurological deficits and were killed 3 days after infusion. Tissues were analyzed for bacteriophage distribution.

Results

Real-time T1-weighted MRI studies of coinfused Gd-DTPA during infusion demonstrated a discrete region of perfusion in both thalamic gray and frontal white matter. An MRI-volumetric analysis revealed that the mean volume of distribution (Vd) to volume of infusion (Vi) ratio of M13 bacteriophage was 2.3 ± 0.2 in gray matter and 1.9 ± 0.3 in white matter. The mean values are expressed ± SD. Immunohistochemical analysis demonstrated mean Vd:Vi ratios of 2.9 ± 0.2 in gray matter and 2.1 ± 0.3 in white matter. The Gd-DTPA accurately tracked M13 bacteriophage distribution (the mean difference between imaging and actual bacteriophage Vd was insignificant [p > 0.05], and was –2.2% ± 9.9% in thalamic gray matter and 9.1% ± 9.5% in frontal white matter). Immunohistochemical analysis revealed evidence of additional spread from the initial delivery site in white matter (mean Vd:Vi, 16.1 ± 9.1). All animals remained neurologically intact after infusion during the observation period, and histological studies revealed no evidence of toxicity.

Conclusions

The CED method can be used successfully and safely to distribute M13 bacteriophage in the brain. Furthermore, additional white matter spread after infusion cessation enhances distribution of this large nanoparticle. Real-time MRI studies of coinfused Gd-DTPA (1 mM) can be used for accurate tracking of distribution during infusion of M13 bacteriophage.

Abbreviations used in this paper:AAV = adenoma-associated virus; AD = Alzheimer disease; CED = convection-enhanced delivery; PBS = phosphate-buffered saline; PD = Parkinson disease; Vd = volume of distribution; Vi = volume of infusion.

Article Information

Address correspondence to: Russell R. Lonser, M.D., Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10, Room 3D20, Bethesda, Maryland 20892-1414. email: lonserr@ninds.nih.gov.

Please include this information when citing this paper: published online May 18, 2012; DOI: 10.3171/.2012.4.JNS111528.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    A: Schematic illustration showing the shape and exterior coat proteins of M13 bacteriophage. The M13 bacteriophage's coat is composed of approximately 3000 copies of major and several copies of minor proteins. This coat surrounds a single-stranded, closed circular DNA. B: Size comparison of M13 bacteriophage (900 nm) relative to albumin (8 nm), AAV (25 nm), and adenovirus (90 to 100 nm).

  • View in gallery

    Immunohistochemical and MRI studies of thalamic infusion. Left: Representative 40-μm brain section showing immunostaining for M13 bacteriophage. This section shows a distinct dark-staining region in the thalamic gray matter without evidence of white matter tracking. The Vd is calculated by adding areas of the stained region in serial sections. Right: Coronal T1-weighted MRI study obtained with contrast agent showing CED to thalamic gray matter of bacteriophage M13 and Gd-DTPA. The distinct hyperintense region shows Gd-DTPA distribution (Vd) and corresponds to the M13 staining seen on immunohistochemical studies.

  • View in gallery

    Magnetic resonance imaging and immunohistochemical studies of the frontal white matter infusion showing M13 bacteriophage distribution and axonal transport. A: Coronal T1-weighted MRI study obtained with contrast agent showing CED to frontal white matter of bacteriophage M13 and Gd-DTPA. The distinct hyperintense region shows Gd-DTPA distribution (Vd) and corresponds only to the dark-staining region seen on immunohistochemical studies. B: Representative 40-μm section showing immunohistochemical staining for bacteriophage M13 in frontal white matter. This section shows a distinct darker-staining region representing the initial infusion, with a lighter-stained region extending through the corpus callosum and to the cortex, representing axonal transport. C: Immunohistochemical staining for bacteriophage M13 at higher magnification (× 10) of inset in panel B, further showing lighter-stained M13 bacteriophage extension emanating from the initial infusion site. D: Immunohistochemical staining for bacteriophage M13 at high magnification (× 40) of inset in panel C, showing fibers (arrows). This is histological evidence for axonal transport.

  • View in gallery

    Graph showing a linear relationship between MRI-confirmed Vd and Vi. There was a linear relationship (R2 = 0.98) between Vi and Vd.

References

1

Alzheimer's and Parkinson's diseases: advances, concepts and new challenges. Proceedings of the 9th International Conference on Alzheimer's and Parkinson's Diseases. Prague, Czech Republic March 11–15, 2009. Neurodegener Dis 7:52152010

2

Asthagiri ARWalbridge SHeiss JDLonser RR: Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer. Laboratory investigation. J Neurosurg 115:4674732011

3

Bankiewicz KSEberling JLKohutnicka MJagust WPivirotto PBringas J: Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164:2142000

4

Bobo RHLaske DWAkbasak AMorrison PFDedrick RLOldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:207620801994

5

Chen MYHoffer AMorrison PFHamilton JFHughes JSchlageter KS: Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg 103:3113192005

6

Croteau DWalbridge SMorrison PFButman JAVortmeyer AOJohnson D: Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. J Neurosurg 102:90972005

7

Deinhardt KSchiavo G: Endocytosis and retrograde axonal traffic in motor neurons. Biochem Soc Symp 721391502005

8

Dimant HSharon NSolomon B: Modulation effect of filamentous phage on alpha-synuclein aggregation. Biochem Biophys Res Commun 383:4914962009

9

Dimant HSolomon B: Filamentous phages reduce alphasynuclein oligomerization in the membrane fraction of SHSY5Y cells. Neurodegener Dis 7:2032052010

10

Fiandaca MSVarenika VEberling JMcKnight TBringas JPivirotto P: Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage 47:Suppl 2T27T352009

11

Frenkel DSolomon B: Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci U S A 99:567556792002

12

Hadaczek PKohutnicka MKrauze MTBringas JPivirotto PCunningham J: Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 17:2913022006

13

Havas DRauter GProkesch MHutter-Paier BWindisch MSolomon B: Effects of filamentous phage treatment on brain pathology of alpha-synuclein tg mice. Neurodegenerative Dis 4:Suppl 11692007. (Abstract)

14

Heiss JDWalbridge SAsthagiri ARLonser RR: Imageguided convection-enhanced delivery of muscimol to the primate brain. Laboratory investigation. J Neurosurg 112:7907952010

15

Kaspar BKLladó JSherkat NRothstein JDGage FH: Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301:8398422003

16

Kells APHadaczek PYin DBringas JVarenika VForsayeth J: Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A 106:240724112009

17

Krauze MTForsayeth JYin DBankiewicz KS: Convection-enhanced delivery of liposomes to primate brain. Methods Enzymol 465:3493622009

18

Lieberman DMLaske DWMorrison PFBankiewicz KSOldfield EH: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82:102110291995

19

MacKay JADeen DFSzoka FC Jr: Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 1035:1391532005

20

Matteoli MVerderio CRossetto OIezzi NCoco SSchiavo G: Synaptic vesicle endocytosis mediates the entry of tetanus neurotoxin into hippocampal neurons. Proc Natl Acad Sci U S A 93:13310133151996

21

Rasched IOberer E: Ff coliphages: structural and functional relationships. Microbiol Rev 50:4014271986

22

Rosenbluth KHLuz MMohr EMittermeyer SBringas JBankiewicz KS: Design of an in-dwelling cannula for convection-enhanced delivery. J Neurosci Methods 196:1181232011

23

Saito RKrauze MTBringas JRNoble CMcKnight TRJackson P: Gadolinium-loaded liposomes allow for realtime magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol 196:3813892005

24

Sanchez CETierney TSGale JTAlavian KNSahin ALee JS: Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum. Laboratory investigation. J Neurosurg 114:6726802011

25

Su XKells APHuang EJLee HSHadaczek PBeyer J: Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 20:162716402009

26

Szerlip NJWalbridge SYang LMorrison PFDegen JWJarrell ST: Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg 107:5605672007

27

Varenika VKells APValles FHadaczek PForsayeth JBankiewicz KS: Controlled dissemination of AAV vectors in the primate brain. Prog Brain Res 175:1631722009

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 64 64 31
Full Text Views 150 150 14
PDF Downloads 109 109 5
EPUB Downloads 0 0 0

PubMed

Google Scholar